Litigation charge hits CooperCompanies (NASDAQ: COO) Q2 EPS despite growth
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
CooperCompanies reported fiscal second quarter 2026 results showing solid underlying growth but a large litigation impact. Revenue was $1.082 billion, up 8% year over year and 5% organically, with both CooperVision and CooperSurgical growing 8%.
GAAP diluted EPS was a loss of $(0.40) versus a profit of $0.44 a year ago, driven by a $271.6 million net pre-tax charge related to product-liability litigation from CooperSurgical’s December 2023 embryo culture media recall. This included $324.1 million of accrued litigation liabilities, partly offset by $52.5 million of expected insurance recoveries.
On a non-GAAP basis, diluted EPS rose 26% to $1.21 and operating margin increased to 27%, reflecting disciplined cost management and benefits from prior reorganization. Free cash flow was $96.4 million, and the company repurchased $13.1 million of stock. Management updated 2026 guidance, targeting total revenue of $4.285–$4.321 billion and non-GAAP EPS of $4.58–$4.66, and reaffirmed a long-term free cash flow objective exceeding $2.2 billion for fiscal 2026–2028.
Positive
- Non-GAAP earnings strength: Fiscal Q2 2026 non-GAAP diluted EPS rose 26% year over year to $1.21, with non-GAAP operating margin improving to 27%, indicating strong underlying profitability despite litigation noise.
- Broad-based revenue growth and guidance: Total Q2 revenue grew 8% to $1.082 billion with 5% organic growth, and management guided fiscal 2026 revenue to $4.285–$4.321 billion with non-GAAP EPS of $4.58–$4.66 and free cash flow over $2.2 billion for 2026–2028.
Negative
- Large litigation charge and GAAP loss: The company recorded a $271.6 million net pre-tax litigation-related charge tied to a prior product recall, driving GAAP diluted EPS to a $(0.40) loss for Q2 2026.
Insights
Strong underlying Q2 performance is overshadowed by a large litigation charge.
CooperCompanies delivered 8% revenue growth to $1.082 billion, with 5% organic growth and stable 68% gross margin. Non-GAAP operating margin improved to 27%, and non-GAAP diluted EPS rose 26% to $1.21, indicating healthy core operations.
The major swing factor is litigation tied to the December 2023 embryo culture media recall at CooperSurgical. Management accrued $324.1 million in litigation liabilities, partly offset by $52.5 million of expected insurance recoveries, producing a $271.6 million net pre-tax charge and a GAAP EPS loss of $(0.40).
Management states settlement agreements now cover over 95% of claimants and expects most payments in fiscal 2026, which helps quantify and time-bound this exposure. Updated fiscal 2026 guidance of $4.285–$4.321 billion revenue and non-GAAP EPS of $4.58–$4.66, plus a free cash flow objective above $2.2 billion for 2026–2028, suggests confidence in post-settlement cash generation, though actual impact depends on execution and remaining legal matters.
8-K Event Classification
3 items: 2.02, 8.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 Revenue: $1.082 billion
GAAP diluted EPS Q2 2026: $(0.40) per share
Non-GAAP diluted EPS Q2 2026: $1.21 per share
+5 more
8 metrics
Q2 2026 Revenue
$1.082 billion
Total revenue, up 8% year over year and 5% organically
GAAP diluted EPS Q2 2026
$(0.40) per share
Down $0.84 from prior-year quarter due to litigation charge
Non-GAAP diluted EPS Q2 2026
$1.21 per share
Up $0.25 or 26% versus last year’s second quarter
Litigation net pre-tax charge
$271.6 million
Recorded within SG&A to resolve product-related claims
Accrued litigation liabilities
$324.1 million
Gross amount accrued related to recall litigation
Expected insurance recoveries
$52.5 million
Offsetting portion of litigation-related costs
Free cash flow Q2 2026
$96.4 million
Cash from operations $182.8M minus $86.4M capex
FY 2026 revenue guidance
$4.285–$4.321 billion
Company-wide revenue outlook with 3.5%–4.5% organic growth
Key Terms
non-GAAP diluted EPS, organic revenue growth, free cash flow, voluntary recall, +2 more
6 terms
non-GAAP diluted EPS financial
"Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter."
Non-GAAP diluted EPS (Earnings Per Share) is a measure of a company's profit allocated to each share of stock, calculated using adjusted earnings that exclude certain items like one-time expenses or gains. It provides a view of ongoing performance by removing irregular or non-recurring factors. Investors use it to better understand the company's core profitability and compare performance across different periods or companies.
organic revenue growth financial
"Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter."
Organic revenue growth is the increase in a company's sales that comes from its existing products and services, without including any gains from acquisitions or selling off parts of the business. It reflects the company’s ability to attract more customers or encourage existing customers to buy more over time. For investors, it indicates the company's underlying strength and efficiency in expanding its core operations.
free cash flow financial
"Cash provided by operations of $182.8 million, offset by capital expenditures of $86.4 million resulted in free cash flow of $96.4 million."
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
voluntary recall regulatory
"In December 2023, CooperSurgical... initiated a voluntary recall of three specific lots of CooperSurgical’s global embryo culture media..."
A voluntary recall is when a company chooses to remove or fix a product that may be unsafe, defective, or mislabeled rather than waiting for a regulator to force action. For investors it matters because it's like a store pulling a damaged item from shelves: it can mean immediate costs, lost sales, repair or replacement expenses, reputational damage, and possibly increased regulatory scrutiny or legal claims that affect future earnings and stock value.
putative class actions regulatory
"As of June 4, 2026, more than 140 lawsuits were filed, including three putative class actions (none of which has been certified)..."
accrued litigation liabilities financial
"consisting of $324.1 million accrued litigation liabilities, partially offset by $52.5 million of expected insurance recoveries."
Earnings Snapshot
Revenue: $1.082 billion · Guidance included
Q2 2026
Revenue
$1.082 billion
+8% year over year
GAAP diluted EPS
$(0.40)
down $0.84 from prior-year quarter
Non-GAAP diluted EPS
$1.21
+26% from prior-year quarter
Non-GAAP operating margin
27%
up 260 basis points from last year
Guidance
Fiscal 2026 revenue of $4.285–$4.321 billion with 3.5%–4.5% organic growth and non-GAAP diluted EPS of $4.58–$4.66.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_______________________________________________
FORM 8-K
_______________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2026
_______________________________________________
(Exact name of registrant as specified in its charter)
_______________________________________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including Zip Code)
(925 ) 460-3600
(Registrant’s telephone number, including area code)
_______________________________________________
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 13(a) of the Exchange Act. ☐
ITEM 2.02. Results of Operations and Financial Condition.
On June 4, 2026, The Cooper Companies, Inc. (the “Company”) issued a press release reporting results for its fiscal second quarter ended April 30, 2026. A copy of this release is attached and incorporated by reference.
This information, including the exhibits(s) hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
The contents of any website or hyperlinks mentioned in the release are for informational purposes only and the contents thereof are not part of the release nor incorporated herein by reference.
ITEM 8.01. Other Events.
As described in its June 4, 2026 press release, the Company recorded a charge as further described below.
In December 2023, CooperSurgical, one of the Company’s two business units, initiated a voluntary recall of three specific lots of CooperSurgical’s LifeGlobalTM global® embryo culture media that it had produced. Subsequently, claims and lawsuits in various U.S. and international jurisdictions were brought by individuals who generally allege that they suffered damages associated with the use of the recalled product, including claims of embryo loss or reduced embryo viability. As of June 4, 2026, more than 140 lawsuits were filed, including three putative class actions (none of which has been certified), and over 1,500 claimants have been proffered to the Company.
Between December 2023 and mid-March 2026, the Company resolved a significant number of claims and lawsuits through settlements which were largely covered by insurance. From mid-March 2026, the Company identified developments, including the procedural acceleration of multiple litigated cases, receipt of additional claimant information, updated damage valuation analysis, and significantly increased projected defense and expert costs, which resulted in a reassessment of exposure. The Company proceeded with negotiations and has reached settlement agreements covering over 95% of claimants. Based on this, management concluded that a loss was probable and reasonably estimable, particularly with respect to potential exposure exceeding available insurance coverage. The net impact to the consolidated statements of operations to resolve outstanding claims was $271.6 million, consisting of $324.1 million accrued litigation liabilities, partially offset by $52.5 million of expected insurance recoveries. The net amount was recorded within Selling, General and Administrative expenses. The Company currently expects the majority of the payments to be made during fiscal 2026.
ITEM 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are furnished herewith:
| Exhibit | Description | ||||
| 99.1 | Press Release dated June 4, 2026 of The Cooper Companies, Inc. | ||||
| 104.1 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE COOPER COMPANIES, INC.
By: /s/ Albert G. White III
Albert G. White III
President & Chief Executive Officer
Dated: June 4, 2026
 | ||||||||
| PRESS RELEASE | ||||||||
CooperCompanies Announces Second Quarter 2026 Results
San Ramon, Calif., June 4, 2026 — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2026.
•Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter.
•Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical.
•Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below.
"We delivered a strong second quarter, achieving record revenue and non-GAAP earnings per share while marking our tenth consecutive quarter of exceeding consensus earnings expectations," said Al White, CooperCompanies' President and CEO. "Our performance reflects solid execution across our businesses, supported by new product launches, favorable demand drivers, and ongoing focus on operational discipline. In addition, we have reached agreements to resolve substantially all of the outstanding claims related to CooperSurgical's fertility media recall, representing an important step in addressing this issue and allowing us to move forward with our strategic review. Moving forward, we are focused on driving sustainable, profitable growth and strong cash flow, while maintaining discipline in a dynamic operating environment."
Second Quarter Operating Results
•Revenue of $1.082 billion, up 8% from last year’s second quarter, up 5% in constant currency, up 5% organically.
•Gross margin of 68% similar to last year's second quarter. On a non-GAAP basis, gross margin was also similar to last year at 68%, with positive FX offsetting higher costs including tariffs.
1
•Operating margin of negative 3% compared with 18% in last year’s second quarter, primarily reflecting higher SG&A expenses, due to a $271.6 million litigation-related charge. On a non-GAAP basis, operating margin was up 260 basis points from last year to 27%, reflecting disciplined execution and meaningful synergies from last year's reorganization.
•Interest expense of $20.9 million compared with $24.2 million in last year's second quarter driven by lower interest rates and lower average debt. On a non-GAAP basis, interest expense was $20.9 million, down from $23.5 million.
•Cash provided by operations of $182.8 million, offset by capital expenditures of $86.4 million resulted in free cash flow of $96.4 million.
Second Quarter CooperVision (CVI) Revenue
•Revenue of $723.5 million, up 8% from last year’s second quarter, up 4% in constant currency, up 4% organically.
•Revenue by category:
| % change y/y | |||||||||||||||||||||||||||||||||||
| (In millions) | Reported | Currency Impact | Constant Currency | Acquisitions and Divestitures | Organic | ||||||||||||||||||||||||||||||
| 2Q26 | |||||||||||||||||||||||||||||||||||
| Toric and multifocal | $ | 364.9 | 11% | (4)% | 7% | —% | 7% | ||||||||||||||||||||||||||||
| Sphere, other | 358.6 | 5% | (4)% | 1% | —% | 1% | |||||||||||||||||||||||||||||
| Total | $ | 723.5 | 8% | (4)% | 4% | —% | 4% | ||||||||||||||||||||||||||||
•Revenue by geography:
| % change y/y | |||||||||||||||||||||||||||||||||||
| (In millions) | Reported | Currency Impact | Constant Currency | Acquisitions and Divestitures | Organic | ||||||||||||||||||||||||||||||
| 2Q26 | |||||||||||||||||||||||||||||||||||
| Americas | $ | 303.2 | 7% | —% | 7% | —% | 7% | ||||||||||||||||||||||||||||
| EMEA | 289.7 | 17% | (11)% | 6% | —% | 6% | |||||||||||||||||||||||||||||
| Asia Pacific | 130.6 | (6)% | —% | (6)% | —% | (6)% | |||||||||||||||||||||||||||||
| Total | $ | 723.5 | 8% | (4)% | 4% | —% | 4% | ||||||||||||||||||||||||||||
Second Quarter CooperSurgical (CSI) Revenue
•Revenue of $358.0 million, up 8% from last year's second quarter, up 6% in constant currency, up 6% organically.
2
•Revenue by category:
| % change y/y | |||||||||||||||||||||||||||||||||||
| (In millions) | Reported | Currency Impact | Constant Currency | Acquisitions and Divestitures | Organic | ||||||||||||||||||||||||||||||
| 2Q26 | |||||||||||||||||||||||||||||||||||
| Office and surgical | $ | 214.2 | 4% | —% | 4% | —% | 4% | ||||||||||||||||||||||||||||
| Fertility | 143.8 | 13% | (3)% | 10% | —% | 10% | |||||||||||||||||||||||||||||
| Total | $ | 358.0 | 8% | (2)% | 6% | —% | 6% | ||||||||||||||||||||||||||||
Other
•During the second quarter, the Company repurchased $13.1 million of common stock, approximately 174 thousand shares, at an average share price of $75.84. The program has $860.8 million of remaining availability.
•Recorded a $271.6 million net pre-tax charge within SG&A related to certain product-related litigation matters associated with a December 2023 voluntary recall of embryo culture media at CooperSurgical, consisting of $324.1 million of accrued litigation liabilities, partially offset by $52.5 million of expected insurance recoveries.
Fiscal Year 2026 Financial Guidance
The Company updated its fiscal year 2026 financial guidance. Details are summarized as follows:
•Fiscal 2026 total revenue of $4.285 - $4.321 billion (organic growth of 3.5% to 4.5%)
•CVI revenue of $2.883 - $2.908 billion (organic growth of 3.5% to 4.5%)
•CSI revenue of $1.402 - $1.414 billion (organic growth of 4% to 5%)
•Fiscal 2026 non-GAAP diluted EPS of $4.58 - $4.66
•Reaffirm previously communicated long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028
Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and certain income or gains and charges or expenses including acquisition and integration costs which we may incur as part of our continuing operations.
With respect to the Company’s guidance expectations, the Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in
3
forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measures. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance.
Reconciliation of Selected GAAP Results to Non-GAAP Results
To supplement our financial results and guidance presented on a GAAP basis, we provide non-GAAP measures such as non-GAAP gross margin, non-GAAP operating margin, non-GAAP diluted earnings per share, as well as constant currency and organic revenue growth because we believe they are helpful for the investors to understand our consolidated operating results. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business, to make operating decisions, and to plan and forecast for future periods. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. We provide further details of the non-GAAP adjustments made to arrive at our non-GAAP measures in the GAAP to non-GAAP reconciliations below. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP.
To present constant currency revenue growth, current period revenue for entities reporting in currencies other than the United States dollar are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year. To present organic revenue growth, we excluded the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures and discontinuations that occurred in the comparable period.
We define the non-GAAP measure of free cash flow as cash provided by operating activities less capital expenditures. We believe free cash flow is useful for investors as an additional measure of liquidity because it represents cash that is available to grow the business, make strategic acquisitions, repay debt, or buyback common stock. Management uses free cash flow internally to understand, manage, make operating decisions and evaluate our business. In addition, we use free cash flow to help plan and forecast future periods.
Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
4
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
GAAP to Non-GAAP Reconciliation
Gross Margin, Operating Margin, and EPS
| Three Months Ended April 30, | Six Months Ended April 30, | |||||||||||||||||||||||||
| (In millions) | 2026 | Margin % | 2025 | Margin % | 2026 | Margin % | 2025 | Margin % | ||||||||||||||||||
| GAAP Gross Profit | $ | 735.4 | 68 | % | $ | 679.1 | 68 | % | $ | 1,430.6 | 68 | % | $ | 1,339.3 | 68 | % | ||||||||||
Acquisition and integration-related charges (1) | — | — | % | 2.2 | — | % | — | — | % | 3.8 | — | % | ||||||||||||||
Exit of business (2) | — | — | % | — | — | % | 1.8 | — | % | — | — | % | ||||||||||||||
Medical device regulations (3) | 0.7 | — | % | 0.7 | — | % | 1.4 | — | % | 1.3 | — | % | ||||||||||||||
| Total | 0.7 | — | % | 2.9 | — | % | 3.2 | — | % | 5.1 | — | % | ||||||||||||||
| Non-GAAP Gross Profit | $ | 736.1 | 68 | % | $ | 682.0 | 68 | % | $ | 1,433.8 | 68 | % | $ | 1,344.4 | 68 | % | ||||||||||
| Three Months Ended April 30, | Six Months Ended April 30, | |||||||||||||||||||||||||
| (In millions) | 2026 | Margin % | 2025 | Margin % | 2026 | Margin % | 2025 | Margin % | ||||||||||||||||||
| GAAP Operating Income (Loss) | $ | (31.0) | (3) | % | $ | 184.8 | 18 | % | $ | 181.8 | 9 | % | $ | 366.8 | 19 | % | ||||||||||
| Amortization of acquired intangibles | 47.7 | 4 | % | 49.8 | 5 | % | 95.6 | 5 | % | 99.4 | 5 | % | ||||||||||||||
Acquisition and integration-related charges (1) | — | — | % | 9.6 | 1 | % | — | — | % | 13.9 | 1 | % | ||||||||||||||
Exit of business (2) | — | — | % | — | — | % | 1.8 | — | % | — | — | % | ||||||||||||||
Medical device regulations (3) | 2.6 | — | % | 5.3 | 1 | % | 6.9 | — | % | 10.7 | — | % | ||||||||||||||
Business optimization charges (4) | 1.1 | — | % | — | — | % | 3.0 | — | % | — | — | % | ||||||||||||||
Other (5) | 276.8 | 26 | % | — | — | % | 283.5 | 13 | % | 0.6 | — | % | ||||||||||||||
| Total | 328.2 | 30 | % | 64.7 | 7 | % | 390.8 | 18 | % | 124.6 | 6 | % | ||||||||||||||
| Non-GAAP Operating Income | $ | 297.2 | 27 | % | $ | 249.5 | 25 | % | $ | 572.6 | 27 | % | $ | 491.4 | 25 | % | ||||||||||
| Three Months Ended April 30, | Six Months Ended April 30, | |||||||||||||||||||||||||
| (In millions, except per share amounts) | 2026 | EPS | 2025 | EPS | 2026 | EPS | 2025 | EPS | ||||||||||||||||||
| GAAP Net Income (Loss) | $ | (77.9) | $ | (0.40) | $ | 87.7 | $ | 0.44 | $ | 52.9 | $ | 0.27 | $ | 192.0 | $ | 0.96 | ||||||||||
| Amortization of acquired intangibles | 47.7 | 0.24 | 49.8 | 0.24 | 95.6 | 0.48 | 99.4 | 0.49 | ||||||||||||||||||
Acquisition and integration-related charges (1) | — | — | 9.6 | 0.05 | — | — | 13.9 | 0.07 | ||||||||||||||||||
Exit of business (2) | — | — | — | — | 1.8 | 0.01 | — | — | ||||||||||||||||||
Medical device regulations (3) | 2.6 | 0.01 | 5.3 | 0.02 | 6.9 | 0.03 | 10.7 | 0.05 | ||||||||||||||||||
Business optimization charges (4) | 1.1 | 0.01 | — | — | 3.0 | 0.02 | — | — | ||||||||||||||||||
Other (5) | 277.6 | 1.42 | 17.4 | 0.09 | 285.2 | 1.46 | 19.9 | 0.10 | ||||||||||||||||||
| Tax effects related to the above items | (55.4) | (0.28) | (11.1) | (0.06) | (70.6) | (0.36) | (25.8) | (0.13) | ||||||||||||||||||
Intra-entity asset transfers (6) | 41.7 | 0.21 | 34.8 | 0.18 | 79.6 | 0.40 | 67.8 | 0.34 | ||||||||||||||||||
| Total | 315.3 | 1.61 | 105.8 | 0.52 | 401.5 | 2.04 | 185.9 | 0.92 | ||||||||||||||||||
| Non-GAAP Net Income | $ | 237.4 | $ | 1.21 | $ | 193.5 | $ | 0.96 | $ | 454.4 | $ | 2.31 | $ | 377.9 | $ | 1.88 | ||||||||||
| Weighted average diluted shares used | 195.6 | 200.7 | 196.1 | 200.9 | ||||||||||||||||||||||
EPS, amounts and percentages may not sum or recalculate due to rounding.
(1) There were no acquisition and integration-related charges in the three and six months ended April 30, 2026.
5
The acquisition and integration-related charges in fiscal 2025 were primarily related to the obp Surgical and Cook Medical acquisition and integration expenses. Charges included $3.5 million and $4.8 million related to redundant personnel costs for transitional employees, $1.1 million and $2.4 million of professional services fees, $1.2 million and $2.1 million of inventory fair value step-up amortization, $1.1 million and $1.8 million of facility rationalization costs, and $0.3 million and $0.4 million of other acquisition and integration-related activities in the three and six months ended April 30, 2025. The three months ended April 30, 2025 also included $2.4 million of acquisition-related non-cash cumulative true-up adjustments reflecting changes in compensation.
Charges in this category may include the direct effects of acquisition accounting, such as amortization of inventory fair value step-up, professional services fees, regulatory fees, and items related to integrating acquired businesses, such as redundant personnel costs for transitional employees, acquisition-related non-cash cumulative true up adjustments reflecting changes in compensation, other acquisition-related costs, integration-related professional services, long-lived asset write-offs, manufacturing integration costs, legal entity and facility rationalization, and other integration-related activities.
(2) There were no charges related to the exit of business in the three months ended April 30, 2026. The six months ended April 30, 2026 included $1.7 million of specifically-identified long-lived asset write-offs and $0.1 million of other costs related to product line exits.
There were no exit of business charges in the three and six months ended April 30, 2025.
Charges in this category may include costs related to product line exits such as inventory write-offs, employee severance costs, and specifically-identified long-lived asset write-offs.
(3) Charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations and the E.U. in vitro diagnostic medical device regulation (collectively, the "Medical device regulations") for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be limited to a specific time period.
(4) Charges included $1.1 million and $2.3 million of redundant personnel costs for transitional employees in the three and six months ended April 30, 2026. The six months ended April 30, 2026 also included $0.4 million of employee severance costs and $0.3 million of other business optimization charges.
There were no business optimization charges in the three and six months ended April 30, 2025.
Charges in this category represent costs associated with initiatives to increase efficiency and optimize the cost structure, and may include, among other items, changes to our IT infrastructure and operations, employee severance costs, redundant personnel costs for transitional employees, legal entity and other business reorganizations, and inventories associated with the business optimization activities.
(5) Charges included $4.5 million and $11.2 million related to legal matters and $0.9 million and $1.8 million of gains and losses on minority interest investments in the three and six months ended April 30, 2026. The three months ended April 30, 2026 also included $272.2 million related to litigation expense and associated legal costs.
Charges in the three months ended April 30, 2025 included $16.7 million of gains and losses on minority interest investments, of which $15.7 million was related to loss on disposal of a minority interest investment, and $0.7 million of accretion of interest attributable to acquisition installment payables. Charges in the six months ended April 30, 2025 included $17.9 million of gains and losses on a minority interest investment, $1.4 million of accretion of interest attributable to acquisition installment payables, and $0.6 million legal fees.
Charges in this category may include legal matters, litigation expense, and other items that are not part of ordinary operations. The adjustments to arrive at non-GAAP net income also include gains and losses on minority interest investments and accretion of interest attributable to acquisition installment payables.
(6) In fiscal 2021, the Company transferred its CooperVision intellectual property and goodwill to its UK subsidiary. As a result, we recorded a deferred tax asset equal to approximately $2.0 billion as a one-time tax benefit in accordance with U.S. GAAP in fiscal 2021 as subsequently adjusted for changes in UK tax law. The non-GAAP adjustments reflect the ongoing net deferred tax benefit from tax amortization each period under UK tax law.
Audio Webcast and Conference Call
The Company will host an audio webcast today for the public, investors, analysts and news media to discuss its second quarter results and current corporate developments. The audio webcast will be broadcast live on CooperCompanies' website, www.investor.coopercos.com, at approximately 5:00 PM ET. It will also be available for replay on CooperCompanies' website, www.investor.coopercos.com. Alternatively, you can dial in to the conference call at 800-715-9871; conference ID 6529381.
6
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including our fiscal year 2026 financial guidance, are forward looking. In addition, all statements regarding anticipated growth in our revenues, expected savings from reorganization activities, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.
Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts, including the ongoing conflict in the Middle East, and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, or around, affected countries; our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements; the actual imposition or threats of tariffs, customs duties and fees by the U.S. government and other nations in response and other retaliatory actions,
7
such as trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers, as well as the impact of the Company’s efforts to mitigate the effects of such tariffs or similar measures; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 and the California Consumer Privacy Act in the U.S. and the General Data Protection Regulation requirements in Europe, including but not limited to those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; a successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation
8
(MDR) and the EU In Vitro Diagnostic Medical Devices Regulation; legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products; risks related to environmental, social and corporate governance issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our United States Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025, as such Risk Factors may be updated in annual and quarterly filings.
We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any obligation to update or revise them except as required by law.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com
9
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Balance Sheets
(In millions)
(Unaudited)
| April 30, 2026 | October 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 138.8 | $ | 110.6 | |||||||
| Trade receivables, net | 809.2 | 829.0 | |||||||||
| Inventories | 896.4 | 846.0 | |||||||||
| Prepaid expense and other current assets | 455.4 | 320.8 | |||||||||
| Total current assets | 2,299.8 | 2,106.4 | |||||||||
| Property, plant and equipment, net | 2,132.2 | 2,082.0 | |||||||||
| Goodwill | 3,888.5 | 3,853.4 | |||||||||
| Other intangibles, net | 1,494.3 | 1,586.3 | |||||||||
| Deferred tax assets | 1,994.7 | 2,077.5 | |||||||||
| Other assets | 672.8 | 689.2 | |||||||||
| Total assets | $ | 12,482.3 | $ | 12,394.8 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Short-term debt | $ | 598.9 | $ | 47.8 | |||||||
| Accounts Payable | 233.3 | 300.4 | |||||||||
| Employee compensation and benefits | 165.9 | 210.6 | |||||||||
| Deferred revenue | 127.9 | 127.9 | |||||||||
Accrued litigation liability | 324.8 | 0.7 | |||||||||
| Other current liabilities | 353.9 | 425.4 | |||||||||
| Total current liabilities | 1,804.7 | 1,112.8 | |||||||||
| Long-term debt | 1,861.3 | 2,457.5 | |||||||||
| Deferred tax liabilities | 96.4 | 93.3 | |||||||||
| Long-term tax payable | 5.6 | 7.5 | |||||||||
| Deferred revenue | 208.8 | 201.8 | |||||||||
Other liabilities | 266.4 | 282.8 | |||||||||
| Total liabilities | 4,243.2 | 4,155.7 | |||||||||
| Stockholders’ equity | 8,239.1 | 8,239.1 | |||||||||
| Total liabilities and stockholders' equity | $ | 12,482.3 | $ | 12,394.8 | |||||||
10
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Statements of Income (Loss)
(In millions, except per share amounts)
(Unaudited)
| Three Months Ended April 30, | Six Months Ended April 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net sales | $ | 1,081.5 | $ | 1,002.3 | $ | 2,105.6 | $ | 1,967.0 | |||||||||||||||
| Cost of sales | 346.1 | 323.2 | 675.0 | 627.7 | |||||||||||||||||||
| Gross profit | 735.4 | 679.1 | 1,430.6 | 1,339.3 | |||||||||||||||||||
| Selling, general and administrative expense | 676.2 | 399.0 | 1,066.4 | 786.9 | |||||||||||||||||||
| Research and development expense | 42.5 | 45.5 | 86.8 | 86.2 | |||||||||||||||||||
| Amortization of intangibles | 47.7 | 49.8 | 95.6 | 99.4 | |||||||||||||||||||
| Operating income (loss) | (31.0) | 184.8 | 181.8 | 366.8 | |||||||||||||||||||
| Interest expense | 20.9 | 24.2 | 43.3 | 50.2 | |||||||||||||||||||
| Other (income) expense, net | (3.5) | 16.1 | (5.3) | 18.8 | |||||||||||||||||||
| Income (loss) before income taxes | (48.4) | 144.5 | 143.8 | 297.8 | |||||||||||||||||||
| Provision for income taxes | 29.5 | 56.8 | 90.9 | 105.8 | |||||||||||||||||||
Net income (loss) | $ | (77.9) | $ | 87.7 | $ | 52.9 | $ | 192.0 | |||||||||||||||
Earnings (loss) per share - diluted | $ | (0.40) | $ | 0.44 | $ | 0.27 | $ | 0.96 | |||||||||||||||
Number of shares used to compute diluted earnings (loss) per share | 195.0 | 200.7 | 196.1 | 200.9 | |||||||||||||||||||
EPS, amounts and percentages may not sum or recalculate due to rounding.
11
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
GAAP to Non-GAAP Reconciliation
Constant Currency Revenue Growth and Organic Revenue Growth
Net Sales
| % change y/y | |||||||||||||||||||||||||||||||||||
| (In millions) | Reported | Currency Impact | Constant Currency | Acquisitions and Divestitures | Organic | ||||||||||||||||||||||||||||||
| 2Q26 | |||||||||||||||||||||||||||||||||||
| CooperVision | $ | 723.5 | 8 | % | (4) | % | 4 | % | — | % | 4 | % | |||||||||||||||||||||||
| CooperSurgical | 358.0 | 8 | % | (2) | % | 6 | % | — | % | 6 | % | ||||||||||||||||||||||||
| Total | $ | 1,081.5 | 8 | % | (3) | % | 5 | % | — | % | 5 | % | |||||||||||||||||||||||
12
FAQ
How did CooperCompanies (COO) perform financially in Q2 2026?
CooperCompanies generated Q2 2026 revenue of $1.082 billion, up 8% year over year with 5% organic growth. However, a large litigation-related charge led to a GAAP diluted EPS loss of $(0.40), while non-GAAP diluted EPS rose to $1.21.
How many claims and lawsuits has CooperCompanies faced from the CooperSurgical recall?
As of June 4, 2026, CooperCompanies reported more than 140 lawsuits, including three uncertified putative class actions, and over 1,500 claimants related to the CooperSurgical embryo culture media recall. Management stated it has settlement agreements covering over 95% of claimants.
What are CooperCompanies’ fiscal 2026 revenue and EPS guidance ranges?
For fiscal 2026, CooperCompanies guides total revenue to $4.285–$4.321 billion, with CooperVision at $2.883–$2.908 billion and CooperSurgical at $1.402–$1.414 billion. Non-GAAP diluted EPS is projected between $4.58 and $4.66, excluding specified non-GAAP adjustments.
How did CooperVision and CooperSurgical segments perform in Q2 2026?
CooperVision posted Q2 2026 revenue of $723.5 million, up 8% reported and 4% organically. CooperSurgical delivered $358.0 million in revenue, also up 8% reported and 6% organically, with fertility revenue growing 13% reported and 10% organically.